TY - JOUR
T1 - The current state of prostate-specific antigen testing
AU - Lewis, Ryan
AU - Hornberger, Brad
PY - 2016
Y1 - 2016
N2 - Since prostate-specific antigen (PSA) testing was approved in 1994, the incidence of metastasis and mortality from prostate cancer have significantly decreased. However, PSA screening for prostate cancer has limitations and few large randomized controlled trials have been conducted to determine the mortality benefit of PSA screening. Two studies that have been conducted are the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC). These were the two main studies the US Preventive Services Task Force (USPSTF) used in its recommendation against prostate cancer screening in 2012. However, new evidence has demonstrated that the PLCO trial had significant limitations and the results of the ERSPC trial were more significant than previously thought. This article describes the strengths and weaknesses of the USPSTF's recommendation, along with current guidelines for prostate cancer screening.
AB - Since prostate-specific antigen (PSA) testing was approved in 1994, the incidence of metastasis and mortality from prostate cancer have significantly decreased. However, PSA screening for prostate cancer has limitations and few large randomized controlled trials have been conducted to determine the mortality benefit of PSA screening. Two studies that have been conducted are the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC). These were the two main studies the US Preventive Services Task Force (USPSTF) used in its recommendation against prostate cancer screening in 2012. However, new evidence has demonstrated that the PLCO trial had significant limitations and the results of the ERSPC trial were more significant than previously thought. This article describes the strengths and weaknesses of the USPSTF's recommendation, along with current guidelines for prostate cancer screening.
KW - Guidelines
KW - Prostate cancer
KW - Prostate-specifi c antigen
KW - PSA
KW - Testing
KW - US Preventive Services Task Force
UR - http://www.scopus.com/inward/record.url?scp=84992089856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992089856&partnerID=8YFLogxK
U2 - 10.1097/01.JAA.0000490955.33308.6e
DO - 10.1097/01.JAA.0000490955.33308.6e
M3 - Article
C2 - 27575906
AN - SCOPUS:84992089856
VL - 29
SP - 51
EP - 53
JO - Journal of the American Academy of Physician Assistants
JF - Journal of the American Academy of Physician Assistants
SN - 1547-1896
IS - 9
ER -